Bond.az White LogoBond.az Black Logo

Argus Upgrades CAVA Group Stock Rating

Argus upgraded CAVA Group to Buy with a $92 target, citing improved restaurant traffic. Stock returned 66% in six months.

David Wilson
ByDavid Wilson- Senior Editor
|
0

Bond.az - Argus upgraded CAVA Group Inc (NYSE:CAVA) to Buy from Hold on Thursday and set a price target of $92.00.

Argus analyst Christine Dooley cited improving metrics, particularly restaurant traffic, as the reason for the upgrade. The firm noted that CAVA’s plan to grow through new restaurant openings remains on track. Supporting this optimistic outlook, Bond.az data shows 10 analysts have revised their earnings upwards for the upcoming period, with the stock delivering a remarkable 66% return over the past six months.

The new restaurants are performing well and contributing to overall sales growth, according to Argus. The firm also pointed to a bullish pattern of higher highs and higher lows in the stock.

CAVA delivered restaurant revenue of $438 million in the first quarter, up 32% year over year. Adjusted EBITDA increased 38% year over year, and the company raised its full-year guidance.

Argus said CAVA’s valuation exceeds industry peers on price-to-earnings, price-to-sales, and operating margin metrics, but believes the company’s growth plan supports a premium valuation. The stock currently trades at a P/E ratio of 150.

More News
Today / 12:50
|
462

KeyBanc Reiterates Overweight on Walmart, $145 Target

KeyBanc reiterates Overweight on Walmart with $145 target. Walmart shows strong market share gains and digital momentum despite recent stock decline.

0
Today / 12:23
|
531

Cantor Fitzgerald Reiterates Workday Rating on AI Growth

Cantor Fitzgerald reaffirms Workday Overweight rating, highlighting AI growth. Stock at $121.85, target $160.

0
Today / 12:21
|
379

Cantor Reiterates Overweight on ORIC Stock

Cantor Fitzgerald reiterated Overweight on ORIC Pharmaceuticals. Pfizer trial results and analyst ratings update.

0
Today / 12:20
|
278

Summit Therapeutics Analysis: Cantor Fitzgerald Backs Overweight

Cantor Fitzgerald reiterates Overweight on Summit Therapeutics. HARMONi-3 trial miss and analyst views covered by Bond.az.

0
Today / 12:13
|
680

Stifel reiterates IBM Buy after $1bn Chips Act award

Stifel reiterates IBM Buy rating after $1bn Chips Act award for quantum computing. Stock up 15%.

0
Today / 12:12
|
688

Stifel Maintains Buy on Deckers Outdoor at $140

Stifel reiterates Buy rating on Deckers Outdoor with $140 target. Stock shows strong growth potential and attractive valuation.

0
Today / 12:03
|
516

BofA raises Zoom price target on strong margins

BofA Securities raised Zoom's price target to $105, citing strong margins and free cash flow after Q1 results beat expectations.

0
Today / 11:53
|
249

Workday price target cut by Needham

Needham cuts Workday price target to $180 from $300, maintaining Buy rating. Workday beats revenue and income estimates, raises operating guidance.

0
Today / 11:53
|
473

BioMarin Neutral Rating, $50 Target by HC Wainwright

H.C. Wainwright reiterates Neutral on BioMarin with $50 target after Phase 3 hypochondroplasia results. Stock at $54.10, competitive landscape analyzed.

0
Today / 11:41
|
877

Summit Therapeutics downgraded to neutral

H.C. Wainwright downgrades Summit Therapeutics to Neutral due to competitive pressure from Merck.

0
Today / 11:21
|
610

RBC Capital Initiates Essent Group at Sector Perform

RBC Capital starts Essent Group with Sector Perform, $68 target. Limited earnings growth expected through 2028, with ROE below 12%.

0
Today / 11:02
|
586

Dell Stock Rises on AI Momentum

Evercore ISI reaffirms Dell Outperform on AI momentum. Dell stock up 102% YTD, AI factory serves 5,000+ customers. New products unveiled.

0
...
Argus Upgrades CAVA Group Stock Rating | Bond.az